March 2, 2020 from 2:30 p.m. - 3:30 p.m. ET
NCCIH will host a pre-application technical assistance webinar on RFA-AT-20-004: HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional). This Funding Opportunity Announcement (FOA) is a reissue of previous announcement RFA-AT-19-004. The purpose of this technical assistance videocast is to provide more detail about this funding opportunity and review specific criteria. All videocast registrants will have the opportunity to submit their questions to our webinar mailbox during the videocast at NCCIHHEAL@mail.nih.gov. The videocast will take place from 2:30 p.m. to 3:30 p.m. ET.
Please register using this Eventbrite link.
This FOA encourages UG3/UH3 phased cooperative research applications to conduct efficient, large-scale pragmatic or implementation trials to improve pain management and reduce the unnecessary use of opioid medications. Please note:
- Awards made under this FOA will initially support a 1-year, milestone-driven, planning phase (UG3), with possible transition to an implementation phase (UH3) of up to 4 years’ duration (5 years total for the two phases).
- UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase.
- The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA.
- The overall goal of this initiative is to support the “real world” assessment of health care strategies and clinical practices, and procedures in health care systems that may lead to improved pain management along with a reduction in unnecessary opioid prescribing.
- Results from the pragmatic trials supported by this reissue should inform policy makers, payers, doctors, and patients in the primary care, emergency department, hospital, or dental setting. This FOA requires that the intervention under study be embedded into health care delivery system, “real world” settings.
- Studies can propose to integrate multi-modal or multiple interventions that have demonstrated efficacy into health care systems, or implement health care system changes to improve adherence to evidence-based guidelines.
- Trials should be conducted across three or more health care systems (HCS) and will become part of and work with the NIH HCS Research Collaboratory supported through the NIH Common Fund. (See https://commonfund.nih.gov/hcscollaboratory.) The NIH HCS Research Collaboratory Program has established a Collaboratory Coordinating Center (CCC) that is providing national leadership and technical expertise in all aspects of research with HCS. Awarded applicants will work with the HCS CCC (http://rethinkingclinicaltrials.org/about-nih-collaboratory/) to facilitate further planning and refinement of the proposed study in partnerships with health care delivery systems.